Vasoactive Intestinal Peptide (VIP) is a naturally occurring neuropeptide consisting of 28 amino acids. While it was initially discovered in the gastrointestinal tract, research through 2026 has solidified its reputation as a “master regulator” of the immune, nervous, and endocrine systems.

Below is a breakdown of its reported benefits, clinical data, and safety profile.

1. Key Therapeutic Benefits

VIP is primarily used for its immunomodulatory and anti-inflammatory properties. Unlike standard anti-inflammatories that simply suppress the immune system, VIP helps restore balance.

• Chronic Inflammatory Response Syndrome (CIRS): Often used in the “Shoemaker Protocol” for mold illness, VIP helps lower inflammatory markers like C4a and TGF-beta 1 while restoring normal levels of MSH (Melanocyte-Stimulating Hormone).
• Neuroprotection & Cognitive Clarity: VIP reduces neuroinflammation, which is linked to “brain fog,” memory deficits, and executive dysfunction. It helps repair the blood-brain barrier and supports neuronal survival.
• Respiratory Support: It acts as a potent vasodilator and bronchodilator. Investigational data (including the synthetic form Aviptadil) show benefits for pulmonary hypertension, asthma, and severe lung injury (including recovery from viral respiratory distress).
• Gut Health: VIP regulates gastrointestinal motility and helps maintain the integrity of the gut lining (“tight junctions”), potentially aiding in “leaky gut” and IBS symptoms.
• Circadian Rhythm Regulation: It plays a critical role in the suprachiasmatic nucleus (the brain’s master clock), helping to synchronize sleep-wake cycles.

2. Clinical Data & Research Reports

Recent data from 2024–2026 highlights several specific shifts in the medical understanding of VIP:

The Transcriptomic Shift
Research (Shoemaker et al.) using RNA-Seq technology has shown that VIP therapy can actually “turn off” genes associated with innate immune activation. Patients treated with VIP nasal spray showed a normalization of ribosomal and mitochondrial gene expression, effectively shifting the body from a “cell danger response” back to a healing state.

Metabolic & Glucose Regulation
Clinical trials have explored VIP’s interaction with the VPAC2 receptor in the pancreas. Data suggests it can stimulate insulin secretion in a glucose-dependent manner, meaning it might lower blood sugar without the high risk of hypoglycemia associated with other treatments.

Current Trials & Status

Application	Status (as of 2026)	Key Findings
CIRS / Mold	Off-label (Nasal)	High efficacy in restoring hormonal balance and reducing brain fog.
Pulmonary Hypertension	Investigational	Significant reduction in pulmonary artery systolic pressure (PASP).
Long COVID/ARDS	Fast Track (Aviptadil)	Targeted for its ability to reduce “cytokine storms” in lung tissue.
Idiopathic Rhinitis	Clinical Trial	Being studied for reducing chronic nasal congestion and itching.